Member news

Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.

Aravax announces it will be communicating topline results from its Phase 2 study of its lead product, PVX108 for the treatment of peanut allergy, at major conferences in the US and Europe in November 2026

The Cell and Gene Therapy (CGT) Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its Annual Review.

Brainomix announced new data published in the esteemed American Journal of Respiratory & Critical Care Medicine (AJRCCM)

Medicines Discovery Catapult has appointed Dr Mike Strange as its Chief Executive Officer.

Poolbeg Pharma announces its unaudited interim results for the six months to 30 June 2026.

Poolbeg Pharma reaffirmed that participant recruitment for the POLB 001 TOPICAL trial is progressing well. Following the previously announced six-patient safety cohort, a total of eight participants have now been dosed out of c.30, since the first patient dosed in July 2026.

Global drug development consultancy Boyds has strengthened its Regulatory Affairs team with the appointment of two senior specialists.

To mark World Cancer Research Day, we are proud to share this film celebrating innovation in immunotherapy, the passion of our team working together in scientific discovery and our shared goal of developing new approaches for patients with cancer.

Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.

Latest Press Release Announcing Momentum Pharma (BIA member organisation) growth, launching a business in Australia to better serve the Australia and APAC region.

Positive interim review marks key milestone for POLB 001 clinical development

New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact. DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.

Engitix announced the appointment of Sonia Quaratino, MD, PhD in the newly created role of Executive Vice President (EVP) Chief Medical Officer (CMO).

PACE and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns

Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.

Analysis for Innovators (A4I) is a funding programme that helps UK SMEs overcome complex measurement, testing and analysis challenges by providing access to world-class expertise, specialist facilities and scientific knowledge from leading UK measurement organisations, including NML.

Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.

Brainomix, a global leader in AI-powered medical imaging, today announced that it has been selected to join Future Fifty, the UK’s most prestigious scale-up programme, recognizing the company as one of the country’s most high-potential technology businesses.

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs